Tuesday, 29 October 2013

Bristol-Myers Squibb announced promising results from phase 2b study of its rheumatoid arthritis drug clazakizumab « New Drug Approvals

Bristol-Myers Squibb announced promising results from phase 2b study of its rheumatoid arthritis drug clazakizumab « New Drug Approvals:

'via Blog this'

No comments:

Post a Comment